Abbott

157 articles with Abbott

• Abbott Confirms Capacity to Support Expanded Use of HeartMate 3™ Heart Pump

  6/3/2021

  - Abbott has the capacity and supply to support increased demand for mechanical circulatory support (MCS) devices following Medtronic's decision to stop the global distribution and sale of the Medtronic HeartWare™ ventricular assist device (HVAD) - Access to MCS devices are critical for advanced heart failure patients and can improve survival, clinical outcomes and quality of life

• Abbott Reports First-Quarter 2021 Results

  4/20/2021

  - Sales growth of 35.3 percent; organic sales growth of 32.9 percent - GAAP diluted EPS growth from continuing operations of 233.3 percent; adjusted diluted EPS growth of 103.1 percent - All four major businesses achieved strong sales growth in the quarter - Projected full-year EPS remains unchanged; reflects growth of more than 35 percent

• Abbott's BinaxNOW™ Rapid Antigen Self Test Receives FDA Emergency Use Authorization for Asymptomatic, Over-the-Counter, Non-Prescription, Multi-Test Use

  4/1/2021

  FDA Emergency Use Authorization permits asymptomatic, non-prescription, over-the-counter self use for people with or without symptoms

• Abbott Reports Fourth-Quarter 2020 Results; Issues Strong Double-Digit Growth Forecast for 2021

  1/27/2021

  - Abbott Sales of $10.7 billion, including $2.4 billion of COVID-19 diagnostic testing-related sales - Sales growth of 28.7 percent; organic sales growth of 28.4 percent - GAAP diluted EPS from continuing operations growth of 103.4 percent; adjusted diluted EPS growth of 52.6 percent - Delivered more than 300 million COVID-19 diagnostics tests in fourth quarter 2020

• Abbott to Launch the NeuroSphere™ myPath™ Digital Health App Designed to Track and Report Pain Relief in Chronic Pain Patients With Physicians Prior to Device Implant

  1/14/2021

  Abbott (NYSE: ABT) today announced the upcoming launch of NeuroSphere™ myPath™, a digital health app designed to track and report on patient perceived pain relief and general well-being associated with spinal cord stimulation (SCS) or dorsal root ganglion (DRG) therapy.

• Abbott Announces Fulfillment of Federal Government Purchase of 150 Million BinaxNOW™ COVID-19 Rapid Tests and Is Now Ready to Support Commercial Distribution

  1/12/2021

  Abbott (NYSE: ABT) is announcing today the fulfillment of the federal government's order of 150 million BinaxNOW™ COVID-19 Ag tests.

• Abbott Receives FDA 510(k) Clearance for the First Rapid Handheld Blood Test for Concussions

  1/11/2021

  - The test to help evaluate mild traumatic brain injury (TBI), commonly known as concussion, produces a result within 15 minutes after a plasma sample is inserted and will run on Abbott's i-STAT™ Alinity™ handheld device - Having a blood test available could help eliminate wait time in the emergency room and could reduce the number of unnecessary CT scans by up to 40%

• As Vaccines Roll Out, Americans See COVID-19 Testing as Important Partner

  12/22/2020

  The development and authorization of a COVID-19 vaccine is a critical scientific milestone in our efforts to combat this pandemic. Abbott released findings from a survey conducted by The Harris Poll, showing that Americans see testing as an essential partner to these new vaccines.

• Abbott to Present at J.P. Morgan Healthcare Conference - Dec 18, 2020

  12/18/2020

  Abbott will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021. Robert B. Ford, president and chief executive officer, will present at 9 a.m. Central time.

• FDA Approves Labeling Update for Abbott's HeartMate 3 Heart Pump for use in Pediatric Patients

  12/17/2020

  - Abbott's HeartMate 3™ heart pump approved for use for pediatric patients battling advanced heart failure - This life-saving technology provides new treatment option for underserved population

• Abbott's BinaxNOW COVID-19 Rapid Test Receives FDA Emergency Use Authorization for First Virtually Guided, At-Home Rapid Test Using eMed's Digital Health Platform

  12/16/2020

  - First at-home, virtually guided service to bring rapid, reliable and affordable testing into the home where the result is delivered in minutes - Abbott and eMed™ expect to deliver and administer 30 million BinaxNOW™ tests in the first quarter of 2021, with an additional 90 million in the second quarter - $25 cost for the test and service is the lowest available for at-home testing, which supports the home user to ensure a successful testing process

• Abbott Receives CE Mark for its COVID-19 IgG Quantitative Antibody Blood Test

  12/15/2020

  - SARS-CoV-2 IgG II Quant antibody test measures levels of IgG antibodies to help measure and understand a person's immune response - The test specifically identifies levels of IgG antibodies that attach to the virus' spike protein which can be helpful to evaluate a person's immune response to vaccines

• Abbott Increases Quarterly Dividend by 25%

  12/11/2020

  - Increase reflects strength and sustainability of Abbott's diversified business - Dividend increased for 49th consecutive year - Abbott remains an S&P 500 Dividend Aristocrat

• Abbott's FreeStyle Libre 2 Now Approved for Adults and Children with Diabetes in Canada, Featuring Unsurpassed 14-Day Accuracy and Optional Alarms

  12/2/2020

  Abbott (NYSE:ABT) today announced its next-generation, sensor-based glucose monitoring technology, FreeStyle Libre 2, received approval by Health Canada for adults and children (4 and older) with diabetes.

• Abbott Becomes First Anchor Sponsor of American Diabetes Association's Health Equity Now Initiative to Advance Access to Care and Technology for People with Diabetes

  11/18/2020

  Today, Abbott (NYSE: ABT) and the American Diabetes Association® (ADA) announced that Abbott has become the first anchor sponsor of the Health Equity Now (HEN) platform to address health disparities for people with diabetes

• Abbott Named Industry Sustainability Leader for the Eighth Year in a Row on the Dow Jones Sustainability Index (DJSI)

  11/16/2020

  For the eighth consecutive year, Abbott (NYSE: ABT) has been named the industry leader in sustainability by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability.

• Abbott Announces the U.S. Launch of the IonicRF™ Generator for Use in Patients Living With Chronic Pain

  11/10/2020

  Abbott (NYSE: ABT) today announced the launch of the IonicRF™ Generator – a new device recently cleared by the U.S. Food and Drug Administration to deliver a non-surgical, minimally invasive treatment for the management of pain in the nervous system.

• Abbott Wins Prestigious Prix Galien USA Award for First-of-its-Kind MitraClip™ Device

  10/30/2020

  -- Considered as the industry's equivalent of the Nobel Prize in biopharmaceutical and medical technology research, Prix Galien USA honored MitraClip as the Best Medical Technology for 2020 -- The groundbreaking MitraClip therapy has positively impacted the lives of more than 100,000 people globally living with mitral regurgitation, or a leaky heart valve

• Abbott Reports Third-Quarter 2020 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance

  10/21/2020

  Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2020.

• Abbott Receives FDA Emergency Use Authorization for its COVID-19 IgM Antibody Blood Test

  10/12/2020

  - Data demonstrates highly reliable test results with 99.56% specificity and 95.00% sensitivity for patients tested 15 days after symptom onset - Availability of the new IgM blood test on the ARCHITECT® and Alinity™ platforms is part of Abbott's effort to offer tests across the disease progression of COVID-19 - Abbott's IgM test will give a more complete picture of where patients are in their recovery   [12-October-202